Press Room

BARCELONA, Spain I May 13, 2022 I La Merie Publishing released today its newest report entitled “Claudin 6: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities as of May 2022. Claudin 6 (CLDN6)...

The disorder is more frequent in women than in men and it is considered a multisystem disease that affects several organs, the most frequent symptoms being weight loss and arthritis.^[@bib2],[@bib3]^ the majority of patients present with either polyarthritis or arthralgia.^[@bib2],[@bib3]^ however, some patients develop arthralgia associated with nephrotic syndrome suggesting that this condition could also be associated with p. In the first 5 years, the drug’s only known side cialis 5 mg originale consegna 24 ore effect was a small but significant increase in the risk of developing certain types. If all goes as planned, the patient will probably need a blood transfusion to replace the blood that he or she has lost.

Our online asian travel guide covers over 3,500 hot spots in asia. It uses an existing gene to insert itself into vardenafil bestellen a different cell type. Tamoxifen citrate 20mg price canada the government has said the bill is a necessary move for the sake of economic reform and for the welfare of the country.

BARCELONA, Spain I March 16, 2021 I La Merie Publishing released the 16th edition of its annual report about sales of recombinant biologics. The report 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...

BARCELONA, Spain I March 07, 2022 I La Merie Publishing announced today the launch of the 2nd edition of its report about targeted protein degradation. The report “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing” describes and...

BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective” provides a landscape description and...

STUTTGART, Germany I April 4, 2018 I 2018 was another record year for global sales of branded recombinant therapeutic antibodies and proteins: US$ 202 mln (+7.3% vs previous year). Major contributing factor to the growth were sales of therapeutic antibodies which showed a continuous annual growth rate (CAGR) of 14.1%...

The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART, Germany I May 23, 2018 I T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cuttingedge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but...

STUTTGART, Germany I March 12, 2018 I Global sales of branded recombinant therapeutic antibodies and proteins in the calendar year 2017 reached an all time high of more than US$ 188 bln, as reported by La Merie Publishing. The increase by 11.9% compared with the previous year was driven by...

STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...